Cargando…

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma

Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chalela, Roberto, Bellosillo, Beatriz, Curull, Víctor, Longarón, Raquel, Pascual-Guardia, Sergi, Badenes-Bonet, Diana, Arriola, Edurne, Sánchez-Font, Albert, Pijuan, Lara, Gea, Joaquim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518197/ https://www.ncbi.nlm.nih.gov/pubmed/30999636 http://dx.doi.org/10.3390/jcm8040529

Ejemplares similares

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

A foreign body reaction to Surgicel(®) in a lymph node diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration
por: Badenes, Diana, et al.
Publicado: (2017)

Bispectral index in hypercapnic encephalopathy associated with COPD exacerbation: a pilot study
por: Chalela, Roberto, et al.
Publicado: (2018)

Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures
por: Pascual-Guardia, Sergi, et al.
Publicado: (2017)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
por: Taus, Álvaro, et al.
Publicado: (2012)

Profile of epigenetic mechanisms in lung tumors of patients with underlying chronic respiratory conditions
por: Mateu-Jimenez, Mercè, et al.
Publicado: (2018)

Adaptive NKG2C+ natural killer cells are related to exacerbations and nutritional abnormalities in COPD patients
por: Pascual-Guardia, Sergi, et al.
Publicado: (2020)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Update on metabolomic findings in COPD patients
por: Gea, Joaquim, et al.
Publicado: (2023)

Influence of COPD systemic environment on the myogenic function of muscle precursor cells in vitro
por: Casadevall, Carme, et al.
Publicado: (2022)

High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients
por: Cañadas, Israel, et al.
Publicado: (2014)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status
por: Planck, Maria, et al.
Publicado: (2013)

Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers
por: TAKAMOCHI, KAZUYA, et al.
Publicado: (2013)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Impact of high-flow oxygen therapy during exercise in idiopathic pulmonary fibrosis: a pilot crossover clinical trial
por: Badenes-Bonet, Diana, et al.
Publicado: (2021)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
por: Prencipe, Berardino, et al.
Publicado: (2023)

Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer
por: Clavé, Sergi, et al.
Publicado: (2023)

[Translated article] Reply to “Absence of Relevant Clinical Effects of SARS-CoV-2 on the Affinity of Hemoglobin for O(2) in Patients With COVID-19”
por: Pascual-Guàrdia, Sergi, et al.
Publicado: (2022)

Respuesta a «Ausencia de efectos clínicos destacables del SARS-CoV-2 sobre la afinidad de la hemoglobina por el O(2) en pacientes con COVID-19»
por: Pascual-Guàrdia, Sergi, et al.
Publicado: (2022)

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma
por: Smits, Alexander J. J., et al.
Publicado: (2012)

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
por: Unni, Arun M, et al.
Publicado: (2015)

Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
por: Yuan, Xiao-Han, et al.
Publicado: (2018)

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
por: Casadevall, David, et al.
Publicado: (2015)

Incidence of pulmonary embolism in patients with non-invasive respiratory support during COVID-19 outbreak
por: González-García, Jose Gregorio, et al.
Publicado: (2021)

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status
por: Kim, Hyojin, et al.
Publicado: (2016)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Ausencia de efectos clínicos destacables del SARS-CoV-2 sobre la afinidad de la hemoglobina por el O(2) en pacientes con COVID-19
por: Pascual-Guàrdia, Sergi, et al.
Publicado: (2021)

Absence of relevant clinical effects of SARS-COV-2 on the affinity of hemoglobin for O(2) in patients with COVID-19()
por: Pascual-Guàrdia, Sergi, et al.
Publicado: (2021)

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma
por: Park, Jangchul, et al.
Publicado: (2016)

Detection of EGFR and KRAS gene mutations using suspension liquid-based cytology specimens in metastatic lung adenocarcinoma
por: Zhao, Huan, et al.
Publicado: (2017)

Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas
por: Simon, Einav, et al.
Publicado: (2017)

Correlation of EGFR or KRAS mutation status with (18)F-FDG uptake on PET-CT scan in lung adenocarcinoma
por: Takamochi, Kazuya, et al.
Publicado: (2017)

Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis
por: Cao, Yajuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ck7og84schvfr960ofmetj5rvk